Alpha-2 macroglobulin (A2M) is a plasma protein in the blood that is naturally produced by the human body.
A2M regulates the immune system to prevent the destruction of cells that produce cartilage. The patient’s blood is drawn, then the A2M is extracted, processed, and injected into the target joints. This treatment helps prevent the degeneration of joint cartilage and is often used in the case of a diagnosis of osteoarthritis or after an injury that might result in osteoarthritis, such as a ruptured ligament.
Based on highly promising recent studies, A2M molecules can potentially considerably slow down the development of osteoarthritis.
Results from the preliminary studies have been positive, and have demonstrated that A2M helps prevent the joint cartilage from breaking down. The FDA is supporting the development of this new treatment.
Patients are expected to require an injection every 6 to 12 months to considerably slow down osteoarthritis.
Click here to read the studies
Disclaimer: As with any medical treatment, results will vary among individuals, and there is no implication that you will heal or receive the same outcome as patients herein. There could be pain or substantial risks involved. These concerns should be discussed with your healthcare provider before any treatment so that you are properly informed and understand that there are no guarantees to healing. The information in this website is offered for educational purposed only and does not imply or give medical advice. The photos used may be models and not patients.
